Products from BPS Bioscience require a minimum order value above 400€
Application: Expression of human B2M HLA-A*02:01 in cells of interest.Generate B2M HLA-A*02:01 expressing cell pools or stable cell lines by puromycin selection.
Background: Human Leukocyte Antigen-A (HLA-A) is an MHC-I (major histocompatibility complex) heavy chain receptor, composed of HLA-A and β2-microglobulin (B2M). There are over 200 genes encoding HLA variants and this variability plays a critical role in adaptive immunity. HLA-A*02 is one of the most common class I types, with more than 300 variants HLA class I involved in presenting peptides that are typically between 8 to 11 amino acids. HLA-A*02:01 can bind 15-mer peptides, which can then be recognized by T cells. Studies in SCLC (small cell lung cancer) patients has shown that an ATAD2 (ATPase family AAA domain-containing protein 2) immunopeptide can be used in HLA-A*02-01-restricted patients with high reactivity. HLA-A*02:01 abilities can be exploited in cancer therapy.
Description: B2M HLA-A*02:01 Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles ready to transduce most mammalian cells, including primary and non-dividing cells. These viruses result in the expression of B2M (beta-2 microglobulin) HLA (human leukocyte antigen)-A*02:01 driven by an EF1a promoter. The lentiviruses also contain a puromycin selection marker (Figure 1).Figure 1. Schematic of the lenti-vector used to generate B2M HLA-A*02:01 Lentivirus.
Formulation: The lentivirus particles were produced in HEK293T cells. They are supplied in medium containing 90% DMEM + 10% FBS. Virus particles can be packaged in custom formulations and produced at higher titers by special request, for an additional fee.
Storage Stability: Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C for up to 12 months from date of receipt. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.
Supplied As: Two vials (500 µl x 2) of lentivirus at a titer ≥107 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.
Target: B2M, HLA
Warnings: BiosafetyThe lentiviruses are produced with a SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and after integration into the genomic DNA of the target cells. of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal and are not present in the lentivirus particle. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS Bioscience recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.
Biosafety Level: BSL-2
SIN Vector?: Yes
References: Hassan C., et al., 2014 J Biol Chem 290(5):2593-2603.Yuan L., et al., 2025 eBioMedicine 112: 105515.